Career | <?phpecho $jobTitle;?> | <?phpecho $companyName;?>

Translational Medicine- Intern

ORIC Pharmaceuticals

South San Francisco, CA, US
  • Job Type: Intern
  • Function: Intern
  • Industry: Biotechnology
  • Post Date: 02/06/2023
  • Website: oricpharma.com
  • Company Address: 240 E. Grand Ave 2nd Floor, South San Francisco, CA, 94080
  • Salary Range: $51,250 - $51,250

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors.

Job Description

ORIC Pharmaceuticals, Inc, is a clinical stage oncology company dedicated to improving patients’ lives and focused on developing treatments that address mechanisms of therapeutic resistance. We are excited to offer an 8–10-week summer internship in the Translational Medicine group to a highly motivated student. You will take part in the translational and biomarker efforts for ORIC’s development programs as member of a multi-disciplinary team, working closely with biomarker, discovery and computational biology scientists. You will study molecular mechanisms of cancer resistance and translate preclinical findings to guide future development of ORIC’s expanding clinical portfolio. Your work will advance understanding of patient and disease heterogeneity and generate insights that advance personalized medicine. The successful candidate will gain an in-depth understanding of drug development, experience working in a fast-moving industry environment with guidance from an experienced mentor in the field of cancer biology. Woman, minorities and individuals from disadvantaged background are encouraged to apply.

 Responsibilities

  • Design and conduct experiments for translational research questions, aimed at characterizing the mechanism of action of ORIC’s lead clinical compounds, identifying target patient populations, and supporting potential combination opportunities in the clinic
  • Conduct comprehensive literature reviews on biomarker strategies relevant to ORIC’s cancer types of focus
  • Keep excellent records of experimental procedures and acquired data in an electronic lab notebook
  • Communicate results verbally and through impactful presentations in cross-functional team meetings and working groups

 Qualifications

  • Major in molecular and cell biology, biochemistry, genetics or a related field (we will consider PhD, masters, or undergraduate students with relevant experience); hands-on laboratory experience is strongly preferred
  • Highly self-motivated and enthusiastic about aspects of drug development and science with a strong focus on quality, details, and results to impact patients’ lives
  • Complements our culture and the standards that guide our daily behavior and decisions: Passion, Excellence, Persistence and Inclusivity
  • Excellent communication, collaboration, and interpersonal skills

 Conditions

  • 30-40 hours per week
  • Laptop provided by company
  • On-site lab work in our South San Francisco Office
  • Must be vaccinated and follow company Covid-19 safety protocol
  • No employment sponsorship
  • No benefits
  • No Relocation/Housing
  • $25/hr.

 

 

 About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

We use cookies to customize your user experience. Click “Agree” if you agree with our Policy.